Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Claes Held

Showing results (141-150 of 227) with videos related to

Pageof 23
Sort By:
American Heart Journal|August 10, 2016
Albuminuria and cardiovascular events in patients with acute coronary syndromes: Results from the TRACER trialAxel Åkerblom, Robert M Clare, Yuliya Lokhnygina, et al.
Journal of the American Heart Association|December 12, 2018
Stroke Outcomes With Vorapaxar Versus Placebo in Patients With Acute Coronary Syndromes: Insights From the TRACER TrialLeo Ungar, Robert M Clare, Fatima Rodriguez, et al.
American Heart Journal|August 21, 2023
Biomarkers and cardiovascular events in patients with stable coronary disease in the ISCHEMIA TrialsJonathan D Newman, Rebecca Anthopolos, Kelly V Ruggles, et al.
JACC. Cardiovascular Interventions|May 11, 2019
Critical Appraisal of Contemporary Clinical Endpoint Definitions in Coronary Intervention Trials: A Guidance DocumentErnest Spitzer, Eugene McFadden, Pascal Vranckx, et al.
American Heart Journal|February 9, 2018
Clinical features and outcomes of patients with type 2 myocardial infarction: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trialPatrícia O Guimarães, Sergio Leonardi, Zhen Huang, et al.
European Heart Journal. Acute Cardiovascular Care|December 14, 2021
Clinical Frailty Scale classes are independently associated with 6-month mortality for patients after acute myocardial infarctionNiklas Ekerstad, Dariush Javadzadeh, Karen P Alexander, et al.
European Heart Journal|November 18, 2011
Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trialRichard C Becker, Jean Pierre Bassand, Andrzej Budaj, et al.
European Heart Journal. Acute Cardiovascular Care|February 21, 2016
Use of thienopyridine prior to presentation with non-ST-segment elevation acute coronary syndrome and association with safety and efficacy of vorapaxar: insights from the TRACER trialRalf E Harskamp, Robert M Clare, Giuseppe Ambrosio, et al.
European Heart Journal. Acute Cardiovascular Care|March 15, 2014
Vorapaxar, a platelet thrombin-receptor antagonist, in medically managed patients with non-ST-segment elevation acute coronary syndrome: results from the TRACER trialClaes Held, Pierluigi Tricoci, Zhen Huang, et al.
American Heart Journal|September 29, 2014
Vorapaxar in patients with peripheral artery disease and acute coronary syndrome: insights from Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER)William Schuyler Jones, Pierluigi Tricoci, Zhen Huang, et al.
Pageof 23

Showing results (141-150 of 227) with videos related to

Sort By:
Pageof 23
American Heart Journal|August 10, 2016
Albuminuria and cardiovascular events in patients with acute coronary syndromes: Results from the TRACER trialAxel Åkerblom, Robert M Clare, Yuliya Lokhnygina, et al.
Journal of the American Heart Association|December 12, 2018
Stroke Outcomes With Vorapaxar Versus Placebo in Patients With Acute Coronary Syndromes: Insights From the TRACER TrialLeo Ungar, Robert M Clare, Fatima Rodriguez, et al.
American Heart Journal|August 21, 2023
Biomarkers and cardiovascular events in patients with stable coronary disease in the ISCHEMIA TrialsJonathan D Newman, Rebecca Anthopolos, Kelly V Ruggles, et al.
JACC. Cardiovascular Interventions|May 11, 2019
Critical Appraisal of Contemporary Clinical Endpoint Definitions in Coronary Intervention Trials: A Guidance DocumentErnest Spitzer, Eugene McFadden, Pascal Vranckx, et al.
American Heart Journal|February 9, 2018
Clinical features and outcomes of patients with type 2 myocardial infarction: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trialPatrícia O Guimarães, Sergio Leonardi, Zhen Huang, et al.
European Heart Journal. Acute Cardiovascular Care|December 14, 2021
Clinical Frailty Scale classes are independently associated with 6-month mortality for patients after acute myocardial infarctionNiklas Ekerstad, Dariush Javadzadeh, Karen P Alexander, et al.
European Heart Journal|November 18, 2011
Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trialRichard C Becker, Jean Pierre Bassand, Andrzej Budaj, et al.
European Heart Journal. Acute Cardiovascular Care|February 21, 2016
Use of thienopyridine prior to presentation with non-ST-segment elevation acute coronary syndrome and association with safety and efficacy of vorapaxar: insights from the TRACER trialRalf E Harskamp, Robert M Clare, Giuseppe Ambrosio, et al.
European Heart Journal. Acute Cardiovascular Care|March 15, 2014
Vorapaxar, a platelet thrombin-receptor antagonist, in medically managed patients with non-ST-segment elevation acute coronary syndrome: results from the TRACER trialClaes Held, Pierluigi Tricoci, Zhen Huang, et al.
American Heart Journal|September 29, 2014
Vorapaxar in patients with peripheral artery disease and acute coronary syndrome: insights from Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER)William Schuyler Jones, Pierluigi Tricoci, Zhen Huang, et al.
Pageof 23